These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 12372582)

  • 1. Effectiveness of multiple antilipidemic agents on Vertical Auto Profile II guided treatment of dyslipoproteinemia.
    Rembold CM; Fan R; Rembold KE; Ayers CR
    Am J Cardiol; 2002 Oct; 90(8):887-90. PubMed ID: 12372582
    [No Abstract]   [Full Text] [Related]  

  • 2. [Therapy of hyperlipoproteinemia in the elderly].
    Parhofer KG; Göke B
    Internist (Berl); 2003 Aug; 44(8):968-76. PubMed ID: 14671811
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Lipid therapy. Prevention of arteriosclerotic cardiovascular diseases].
    Windler E
    Internist (Berl); 2001 Jan; 42(1):92-110. PubMed ID: 11271625
    [No Abstract]   [Full Text] [Related]  

  • 4. Matters of controversy regarding lipid therapy for Japanese patients with coronary artery disease.
    Komiyama M; Wada H; Hasegawa K
    Intern Med; 2014; 53(8):817-8. PubMed ID: 24739600
    [No Abstract]   [Full Text] [Related]  

  • 5. [Current approaches to the diagnosis and correction of atherogenic dyslipoproteinemia].
    Oganov RG; Perova NV
    Kardiologiia; 1989 Oct; 29(10):15-22. PubMed ID: 2615152
    [No Abstract]   [Full Text] [Related]  

  • 6. [Variability of the hypolipidemic action of simvastatin and fluvastatin in patients with primary hyperlipoproteinemia].
    Tvorogova MG; Susekov AV; Semenova OA; Kukharchuk VV; Titov VN
    Ter Arkh; 1998; 70(12):8-13. PubMed ID: 10067240
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of pitavastatin with atorvastatin in increasing HDL-cholesterol and adiponectin in patients with dyslipidemia and coronary artery disease: the COMPACT-CAD study.
    Kurogi K; Sugiyama S; Sakamoto K; Tayama S; Nakamura S; Biwa T; Matsui K; Ogawa H;
    J Cardiol; 2013 Aug; 62(2):87-94. PubMed ID: 23672789
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibition of PCSK9: a novel approach for the treatment of dyslipidemia.
    Stawowy P; Just IA; Kaschina E
    Coron Artery Dis; 2014 Jun; 25(4):353-9. PubMed ID: 24667128
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical results with gemfibrozil.
    Pickering JE
    Am J Cardiol; 1983 Aug; 52(4):39B-40B. PubMed ID: 6351579
    [No Abstract]   [Full Text] [Related]  

  • 10. Focus on HDL as a therapeutic target for CAD risk reduction.
    Davidson MH
    Am J Cardiol; 2009 Nov; 104(10 Suppl):1E-2E. PubMed ID: 19895937
    [No Abstract]   [Full Text] [Related]  

  • 11. [HMG-CoA reductase inhibitors].
    Yamamoto A
    Nihon Rinsho; 2001 Mar; 59 Suppl 3():578-86. PubMed ID: 11347135
    [No Abstract]   [Full Text] [Related]  

  • 12. [Effect of one-year treatment with low simvastatin doses on lipids and Lp(a) in patients with significant hypercholesterolemia].
    Adamska-Dyniewska H; Chojnowska-Jezierska J
    Pol Arch Med Wewn; 1998 May; 99(5):366-72. PubMed ID: 9816885
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Drug therapy for diabetic dyslipoproteinaemia: a practical approach.
    Winocour PH; Laker MF
    Diabet Med; 1990 May; 7(4):292-8. PubMed ID: 2140080
    [No Abstract]   [Full Text] [Related]  

  • 14. [Which study conclusions favor so-called primary prevention of increased cholesterol values, which speak against prevention and what therapy guidelines are reliable?].
    Steinmetz A
    Internist (Berl); 1994 Sep; 35(9):880-1. PubMed ID: 7960571
    [No Abstract]   [Full Text] [Related]  

  • 15. Effect of combination therapy with lipid-reducing drugs in patients with coronary heart disease and "normal" cholesterol levels. A randomized, placebo-controlled trial. Harvard Atherosclerosis Reversibility Project (HARP) Study Group.
    Pasternak RC; Brown LE; Stone PH; Silverman DI; Gibson CM; Sacks FM
    Ann Intern Med; 1996 Oct; 125(7):529-40. PubMed ID: 8815751
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Incremental reduction of serum total cholesterol and low-density lipoprotein cholesterol with the addition of plant stanol ester-containing spread to statin therapy.
    Blair SN; Capuzzi DM; Gottlieb SO; Nguyen T; Morgan JM; Cater NB
    Am J Cardiol; 2000 Jul; 86(1):46-52. PubMed ID: 10867091
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prescription and adherence to statins of patients with coronary artery disease and hypercholesterolemia.
    Mansur AP; Mattar AP; Tsubo CE; Simão DT; Yoshi FR; Daci K
    Arq Bras Cardiol; 2001 Feb; 76(2):111-8. PubMed ID: 11270314
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Relation of coronary calcium progression and control of lipids according to National Cholesterol Education Program guidelines.
    Wong ND; Kawakubo M; LaBree L; Azen SP; Xiang M; Detrano R
    Am J Cardiol; 2004 Aug; 94(4):431-6. PubMed ID: 15325924
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Health-related quality of life and long-term therapy with pravastatin and tocopherol (vitamin E) in older adults.
    Carlsson CM; Papcke-Benson K; Carnes M; McBride PE; Stein JH
    Drugs Aging; 2002; 19(10):793-805. PubMed ID: 12390056
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dyslipoproteinemia in the elderly: to treat or not to treat?
    Hazzard WR
    Am J Med; 1999 Aug; 107(2A):51S-53S. PubMed ID: 10484244
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.